AbbVie Inc. and the Texas University's MD Anderson Cancer Center have entered into a three-year partnership in immuno-oncology. The two will combine their efforts in the discovery of new drugs stimulating the immune system's capabilities to fight cancer by conducting preclinical and clinical trials and evaluating new ideas in the field. AbbVie and MD Anderson will appoint a joint scientific committee, each nominating two members.

The committee will resolve on the projects worth being pursued. The projects are based on AbbVie's oncology programme portfolio.